A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma
7 affiliations
- 1Institute of Physics University of Silesia in Katowice Chorzów Poland
- 2Institute of Chemistry University of Silesia in Katowice Chorzów Poland
- 3Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences Kraków Poland
- 4Department of Biopharmacy Medical University of Lublin Poland
- 5Department of Physical Chemistry, Institute of Chemical Sciences Maria Curie–Skłodowska University in Lublin Poland
- 6Department of Medical Chemistry Medical University of Lublin Poland
- 7Department of Systems Biology and Engineering Silesian University of Technology Gliwice Poland
Abstract
Aberrant signaling through insulin‐like growth factor 1 receptor (IGF1R) and epidermal growth factor receptor (EGFR) drives glioblastoma (GBM) progression and therapy resistance. Herein, we describe the synthesis and biological evaluation of W1B, a novel styrylquinazolinone‐based small‐molecule inhibitor. In antiproliferative assays, W1B exhibited potent submicromolar activity against a panel of GBM cell lines. Kinase assays and binding studies confirmed strong inhibition and high binding affinity toward IGF1R. Molecular docking suggested possible interactions with both IGF1R and EGFR, with W1B adopting distinct binding poses in each kinase domain. In cellular studies, W1B reduced IGF1R and EGFR protein levels in LN229 cells and suppressed Akt phosphorylation. Under high‐glucose conditions, however, W1B only retained inhibitory activity toward IGF1R, resulting in attenuated effects on the Akt/mTOR axis and underscoring the influence of glucose‐dependent signaling rewiring on drug efficacy. Combination studies revealed that W1B acts synergistically with the EGFR inhibitor dacomitinib, effectively overcoming compensatory activation of parallel pathways. Biomimetic lipophilicity and in silico pharmacokinetic analyses indicated that styrylquinazolinone has the potential to cross the blood–brain barrier (BBB). The in vivo studies on Danio rerio have shown a good safety profile, as well as strong antitumor potential of the tested compound. Therefore, these findings establish W1B as a promising derivative for the development of next‐generation dual IGF1R/EGFR inhibitors in GBM.
Related
- A dual-targeting nitrogen mustard-class I HDAC inhibitor hybrid molecule is superior to the combination of an HDAC inhibitor plus chlorambucil in glioblastoma cells
- Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes
- Design, synthesis, and in vitro antiproliferative evaluation of dasatinib/HO-1 inhibitor codrugs towards glioblastoma therapy.
- Vanadate inhibits transcription of the rat insulin receptor gene via a proximal sequence of the 5′flanking region
- Synergy-driven enhancement of sodium borohydride hydrolysis over a one-pot synthesized Co-Ni bimetallic MOF
BibTeX
@article{rurka2026novel,
title = {{A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma}},
author = {Patryk Rurka and Wioleta Cieślik and Wojciech Płaziński and Katarzyna Stępnik and Anna Boguszewska‐Czubara and Elżbieta Kot and Robert Musioł and Mateusz Jasica and Anna Mrozek‐Wilczkiewicz and Katarzyna Malarz},
journal = {Molecular Oncology},
year = {2026},
month = may,
doi = {10.1002/1878-0261.70274},
url = {https://doi.org/10.1002/1878-0261.70274},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma
AU - Patryk Rurka
AU - Wioleta Cieślik
AU - Wojciech Płaziński
AU - Katarzyna Stępnik
AU - Anna Boguszewska‐Czubara
AU - Elżbieta Kot
AU - Robert Musioł
AU - Mateusz Jasica
AU - Anna Mrozek‐Wilczkiewicz
AU - Katarzyna Malarz
PY - 2026
DA - 2026/05/27
JO - Molecular Oncology
DO - 10.1002/1878-0261.70274
UR - https://doi.org/10.1002/1878-0261.70274
AB - Aberrant signaling through insulin‐like growth factor 1 receptor (IGF1R) and epidermal growth factor receptor (EGFR) drives glioblastoma (GBM) progression and therapy resistance. Herein, we describe the synthesis and biological evaluation of W1B, a novel styrylquinazolinone‐based small‐molecule inhibitor. In antiproliferative assays, W1B exhibited potent submicromolar activity against a panel of GBM cell lines. Kinase assays and binding studies confirmed strong inhibition and high binding affinity toward IGF1R. Molecular docking suggested possible interactions with both IGF1R and EGFR, with W1B adopting distinct binding poses in each kinase domain. In cellular studies, W1B reduced IGF1R and EGFR protein levels in LN229 cells and suppressed Akt phosphorylation. Under high‐glucose conditions, however, W1B only retained inhibitory activity toward IGF1R, resulting in attenuated effects on the Akt/mTOR axis and underscoring the influence of glucose‐dependent signaling rewiring on drug efficacy. Combination studies revealed that W1B acts synergistically with the EGFR inhibitor dacomitinib, effectively overcoming compensatory activation of parallel pathways. Biomimetic lipophilicity and in silico pharmacokinetic analyses indicated that styrylquinazolinone has the potential to cross the blood–brain barrier (BBB). The in vivo studies on Danio rerio have shown a good safety profile, as well as strong antitumor potential of the tested compound. Therefore, these findings establish W1B as a promising derivative for the development of next‐generation dual IGF1R/EGFR inhibitors in GBM.
SN - 1574-7891
SN - 1878-0261
ER -